P696: Initiation of Vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A Prospective Study Including Rheumatological and Blinded Imaging Assessments.ECCO'24Year: 2024
Authors: Rohekar, S.(1);Boyd, T.(1);Lambert, R.(2);Beaton, M.(3);Chande, N.(4);Gregor, J.(3);Lennox, H.(5);McIntosh, K.(3);Ponich, T.(3);Rahman, A.(3);Sharma, T.(6);Sey, M.(3);Tauqir, M.(7);Jairath, V.(3)*;
(1)Schulich School of Medicine & Dentistry- Western University, Department of Medicine- Division of Rheumatology, London, Canada;(2)University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, Canada;(3)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(4)Southwestern Ontario Inflammatory Bowel Disease Clinic, Southwestern Ontario Inflammatory Bowel Disease Clinic, London, Canada;(5)London Health Sciences Centre, Gastroenterology, London, Canada;(6)Lawson Health Research Institute, Rheumatology, London, Canada;(7)Schulich School of Medicine & Dentistry- Western University, Schulich School of Medicine & Dentistry, London, Canada;
P697: Short- and long-term outcomes following biologic use before non-conventional stricureplasty for Crohn’s JejunoileitisECCO'24Year: 2024
Authors: Belkovsky, M.(1)*;Cohen, B.(2);Sommovilla, J.(1);Hull, T.(1);Holubar , S.(1);
(1)Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Gastroenterology- Hepatology & Nutrition, Cleveland, United States;
P698: Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentre Real-World Observational Study.ECCO'24Year: 2024
Authors: ParraPhD, R.(1)*;Chebli, J.M.F.(2);Freitas Cardoso de Azevedo, M.(3);Chebli, L.A.(2);Zabot, G.P.(4);Cassol, O.S.(5);Fróes, R.D.S.B.(6);Santana, G.O.(7);Lubini, M.(8);Magro, D.O.(9);Imbrizi, M.(9);Moraes, A.C.S.(10);Teixeira, F.V.(11);Alves Jr, A.J.T.(12);Gasparetti Junior, N.L.T.(13);Ferreira, S.D.C.(14);Queiroz, N.S.F.(15);Kotze, P.G.(16);Féres, O.(17);
(1)University of Sao Paulo, Department of Surgery and Anatomy, Ribeirao Preto, Brazil;(2)Federal University of Juiz de Fora UFJF, Department of Medicine- Inflammatory Bowel Disease Center, Juiz de Fora, Brazil;(3)University of São Paulo School of Medicine, Gastroenterology, São Paulo, Brazil;(4)Moinhos de Vento Hospital- Feevale University, Colorectal Surgery, Porto Alegre, Brazil;(5)Hospital de Clínicas de Passo Fundo- Atitus Medical School, Colorectal Surgery, Passo Fundo, Brazil;(6)Gastromed, Department of Gastroenterology and Endoscopy, Rio de Janeiro, Brazil;(7)State University of Bahia, Gastroenterology, Salvador, Brazil;(8)Passo Fundo University, Gastroenterology, Passo Fundo, Brazil;(9)State University of Campinas UNICAMP, Surgery, Campinas, Brazil;(10)Hospital Copa D´Or. Rio de Janeiro, Internal Medicine, Rio de Janeiro, Brazil;(11)Gastrosaude Clinic, Gastroenterology, Marília, Brazil;(12)Pontifícia Universidade Católica de Campinas, Surgery, Campinas, Brazil;(13)Hospital Vivalle Rede Dor, Surgery, São José dos Campos, Brazil;(14)Ribeirao Preto Medical School- University of São Paulo, Gastroenterology, Ribeirao Preto, Brazil;(15)Health Sciences Graduate Program- Pontifícia Universidade Católica do Paraná PUCPR, IBD Center- Santa Cruz Hospital, Curitiba, Brazil;(16)Health Sciences Postgraduate Program- Pontificia Universidade Católica do Paraná PUCPR, Surgery, Curitiba, Brazil;(17)Ribeirao Preto Medical School- University of São Paulo, Surgery and Anatomy, Ribeirão Preto, Brazil;
P701: Evaluation of the effectiveness of vedolizumab in patients with Crohn@E@s disease: a multicenter real-life study from Argentina.ECCO'24Year: 2024
Authors: Balderramo, D.C.(1)*;Etchevers, J.(2);Fuxman, C.(3);Lubrano, P.(4);Bellicoso, M.(5);Correa, G.(6);Trakal, J.(7);Defago, M.R.(8);Montero, J.(9);Toro, M.(10);Novillo, A.(11);Bonardo, M.(12);Arancibia, N.(13);Motañez, S.(14);Quines, S.(15);Huernos, S.(16);Gil, A.(17);Gonzalez, R.(18);Goncalves, S.(19);
(1)IBD section, Gastroenterology Department. Hospital Privado Universitario de Cordoba. Instituto Universitario de Ciencias Biomedicas de Cordoba, Cordoba, Argentina;(2)Hospital Italiano de Buenos Aires, Gastroenterology Department, Buenos Aires, Argentina;(3)Fundación Favaloro, Gastroenterology Department, Buenos Aires, Argentina;(4)Sanatorio Mater-Dei, Gastroenterology Department, Buenos Aires, Argentina;(5)Inmunología Buenos Aires, Gastroenterology Section, Buenos aires, Argentina;(6)Hospital San Martín de la Plata, IBD section, La Plata, Argentina;(7)Clínica Reina Fabiola, Gastroenterology Department, Cordoba, Argentina;(8)Instituto Humana, Gastroenterology Section, Cordoba, Argentina;(9)Hospital Provincial del Centenario, Gastroenterology Department, Rosario, Argentina;(10)HIGEA Centro Médico, Gastroenterology Department, Mendoza, Argentina;(11)Sanatorio 9 de Julio, Gastroenterology Department, Tucuman, Argentina;(12)Bienestar GECIP, Gastroenterology Department, Cipolletti, Argentina;(13)Sanatorio Argentino, Gastroenterology Department, San Juan, Argentina;(14)Hospital Marcial Quiroga, Gastroenterology Department, San Juan, Argentina;(15)Centro de Estudios Digestivos, Gastroenterology Department, Mar del Plata, Argentina;(16)CEIDI. Consultorio de Enfermedades Inflamatorias del Intestino, IBD section, Buenos Aires, Argentina;(17)CEIDI. Consultorio de Enfermedades Inflamatorias del Intestino., IBD section, Buenos Aires, Argentina;(18)Hospital Aleman, Gastroenterology Department, Buenos Aires, Argentina;(19)CEIDI. Consultorio de Enfermedades Inflamatorias del Intestino. GEDYT, IBD section, Buenos Aires, Argentina;
P702: Long term outcomes following de-escalation of dose-intensified ustekinumab in patients with Crohn’s diseaseECCO'24Year: 2024
Authors: Demase, K.(1)*;Smith, R.L.(1);Luber, R.(1);Taylor, K.M.(1);Ward, M.G.(1);Sparrow, M.P.(1);Little, R.D.(1);
(1)Alfred Health and Monash University, Gastroenterology, Melbourne, Australia;
P703: Comparison of infliximab and adalimumab therapies Persistence in patients with Ulcerative Colitis: Results from a Single Tertiary Turkish IBD Center CohortECCO'24Year: 2024
Authors: Eroglu, Z.(1);Yilmaz, V.(2)*;Guvenir, T.(2);Er, R.E.(2);Toruner, M.(3);
(1)Ankara University School of Medicine, Department of Internal Medicine, Ankara, Turkey;(2)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;(3)Ankara University Medical School- Ibni-sina Hospital, Department of Gastroenterology, Ankara, Turkey;
P704: Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: The SAPPHIRE RegistryECCO'24Year: 2024
Authors: AxelradMD- MPH, J.(1)*;Jiang, Y.(2);Colombel, J.F.(3);Scherl, E.(4);Lukin, D.(4);Chang, S.(1);Chen, L.(5);Katz, S.(1);Kwah, J.(1);Swaminath , A.(6);Sultan, K.(6);Villagra, C.(3);Jandorf, L.(3);Itzkowitz, S.(3);
(1)NYU Grossman School of Medicine, Medicine, New York, United States;(2)Duke University, Practice of Statistical Science, Durham, United States;(3)Icahn School of Medicine at Mount Sinai, Medicine, New York, United States;(4)Weill Cornell Medicine, Medicine, New York, United States;(5)Robert Wood Johnson Medical School, Medicine, New Brunswick, United States;(6)Zucker School of Medicine, Medicine, New York, United States;
P705: Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programmeECCO'24Year: 2024
Authors: Lichtenstein, G.R.(1);Allegretti, J.R.(2);Loftus Jr, E.V.(3);Irving, P.M.(4);Banerjee, R.(5);Charabaty, A.(6);Kuehbacher, T.(7);Bananis, E.(8);Woolcott, J.C.(8);Dalam, A.B.(9);Lazin, K.(10);Keating, M.(11);McDonnell, A.(12);Danese, S.(13)*;
(1)Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia- PA, United States;(2)Brigham and Women’s Hospital, Division of Gastroenterology- Hepatology and Endoscopy, Boston- MA, United States;(3)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester- MN, United States;(4)Guy’s and St Thomas’ Hospital, IBD Unit, London, United Kingdom;(5)Asian Institute of Gastroenterology, Department of Gastroenterology, Hyderabad, India;(6)Johns Hopkins School of Medicine, Division of Gastroenterology and Hepatology, Washington DC, United States;(7)St Marien- and Annastift Hospital, Department of Internal Medicine/Gastroenterology, Ludwigshafen a. Rhein, Germany;(8)., Pfizer Inc, Collegeville- PA, United States;(9)., Pfizer Inc, Manila, Philippines;(10)., Pfizer AG, Zürich, Switzerland;(11)., Pfizer Inc, New York- NY, United States;(12)., Pfizer Ltd, Sandwich, United Kingdom;(13)IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Division of Gastroenterology and Endoscopy, Milan, Italy;
P706: Tofacitinib in Moderate to Severe Ulcerative Colitis patients naïve to biological therapy: A prospective real world analysis of efficacy and safetyECCO'24Year: 2024
Authors: Banerjee, R.(1)*;Dhanush, M.(1);Raghunathan, N.(1);Pal, P.(1);Joshi, V.(1);Patel, R.(1);Godbole, S.(1);Akki, Y.(1);Valluri, S.(1);Nagasuri, P.(1);Haridas, A.(1);
(1)AIG Hospitals, Inflammatory Bowel Disease, Hyderabad, India;
P707: Real-world Long-term efficacy of ustekinumab in the treatment of Perianal Fistulizing Crohn@E@s disease: Results from a single-center retrospective studyECCO'24Year: 2024
Authors: Chen, Q.(1)*;Gong, Y.(1);Yang, F.(2);Qiao, L.(1);Wang, H.(1);Zhang, D.(1);Wang, C.(1);Zhu, Z.(1);Yang, B.(1);
(1)Affiliated Hospital of Nanjing University of Chinese Medicine- Jiangsu Province Hospital of Chinese Medicine, Department of Colorectal Surgery, Nanjing, China;(2)University of New South Wales, School of mathematics and statistics, Sydney, Australia;
P708: Multiple Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes in Inflammatory Bowel Disease: A Real-World Effectiveness Analysis in a National U.S. CohortECCO'24Year: 2024
Authors: Hou, J.K.(1,2)*;Pham, C.(1);Xu, A.(1);Sansgiry, S.(1);Modi, V.(1);Waljee, A.(3,4);
(1)Baylor College of Medicine, Medicine, Houston, United States;(2)Michael E. DeBakey VA Medical Center, Medicine, Houston, United States;(3)University of Michigan, Medicine, Ann Arbor, United States;(4)Ann Arbor VA Healthcare System, Medicine, Ann Arbor, United States;
P709: Role of NOD2 single nucleotide polymorphisms on ustekinumab drug durability in adult patients with Crohn’s diseaseECCO'24Year: 2024
Authors: Elleisy, N.(1)*;Behnisch, S.(1);Huth, A.(1);Schäffler, H.(1);Jaster, R.(1);Lamprecht, G.(1);Reiner, J.(1);
(1)University Hospital Rostock, Department of Gastroenterology, Rostock, Germany;
P710: Prevalence, Characteristics and Management of Patients with Difficult-To-Treat Inflammatory Bowel Disease: A Cross-Sectional Study From a Tertiary Referral CenterECCO'24Year: 2024
Authors: ParigiMD, T.L.(1)*;Massimino, L.(1);Carini, A.(1);Allocca, M.(1);D@E@Amico, F.(1);Furfaro, F.(1);Zilli, A.(1);Peyrin-Biroulet, L.(2);Ungaro, F.(1);Danese, S.(1);
(1)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(2)University of Lorraine, Inserm- NGERE- F-54000, Nancy, France;
P711: Outcomes of Outpatient Biologic Exposed Patients Hospitalized with Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Al-Bawardy, B.(1)*;Al Sulais, E.(2);Mukhtar, M.(3);Hart, A.(3);Raine, T.(4);
(1)King Faisal Specialist Hospital and Research Ceneter, Department of Internal Medicine- Division of Gastroenterology and Hepatology, Riyadh, Saudi Arabia;(2)King Fahad Specialist Hospital, Department of Medicine, Dammam, Saudi Arabia;(3)St. Mark’s Hospital, Department of Gastroenterology, London, United Kingdom;(4)Addenbrooke’s Hospital- University of Cambridge, Department of Gastroenterology, Cambridge, United Kingdom;
P712: Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidenceECCO'24Year: 2024
Authors: Cummings, F.(1)*;Buisson, A.(2);Smith, P.J.(3);Rahmany, S.(4);Subramanian, S.(5);Kwon, B.(6);Park, S.(6);Lee, Y.N.(6);Fumery, M.(7);
(1)Southampton General Hospital, Gastroenterology, Southampton, United Kingdom;(2)Clermont Auvergne University, IBD Unit, Clermont-Ferrand, France;(3)Royal Liverpool Hospital, Gastroenterology, Liverpool, United Kingdom;(4)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(5)Cambridge University Hospital NHS Trust, Gastroenterology, Cambridge, United Kingdom;(6)Celltrion Healthcare, Medical Department, Incheon, Korea- Republic Of;(7)CHU Amiens Picardie, Hepatogastroenterology, Amiens, France;
P713: The introduction of an intestinal ultrasound service significantly reduces diagnostic endoscopy usage in an Inflammatory Bowel Disease service – The SCOPELESS StudyECCO'24Year: 2024
Authors: Feng, G.(1)*;Little, R.(1);Ardalan, Z.(1);Friedman, A.(1);Smith, R.(1);Taylor, K.(1);Sparrow, M.(1);
(1)Alfred Health, Gastroenterology, Melbourne, Australia;
P714: Immunogenicity and safety of adjuvated recombinant zoster vaccine in IBD patients on different immunosuppressive therapies.ECCO'24Year: 2024
Authors: Franco, M.(1)*;De Bona, M.(2);Brun, P.(3);Bortoluzzi, M.(3);Nappo, A.(4);Zaetta, D.(2);Roncen, E.(2);Riguccio, G.(2);Boito, C.(5);Piselli, P.(6);Castagliuolo, I.(3);Savarino, E.V.(7);BudaPhD, A.(8);
(1)Gastroenterology, Gastrointestinal Oncological Surgery, Feltre, Italy;(2)AULSS1 Dolomiti- Gastrointestinal Inflammatory Departimental Unit- S. Maria del Prato Hospital, Gastrointestinal Oncological Surgery, Feltre, Italy;(3)University of Padova, Molecular Medicine, Padova, Italy;(4)INMI- IRCCS L. Spallanzani, Epidemiology and Preclinical Research, Roma, Italy;(5)Aulss1 Dolomiti- Laboratory Medicine- Santa Maria del Prato Hospital, Pathology and Laboratory Medicine, Feltre, Italy;(6)INMI L. Spallanzani- IRCCS, Epidemiology and Preclinical Research, Roma, Italy;(7)University of Padova, Oncological Gastrointestinal Surgical Sciences, Padova, Italy;(8)AULSS1 Dolomiti- Gastroenterology- S. Maria del Prato Hospital, Gastrointestinal Oncological Surgery, Feltre, Italy;
P715: Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictorsECCO'24Year: 2024
Authors: Privitera, G.(1)*;Parisio, L.(2);Perniola, S.(3);Varca, S.(4);Alivernini, S.(5);Tolusso, B.(6);Petito, V.(4);Napolitano, D.(2);Schiavoni, E.(2);Scaldaferri, F.(2);Gasbarrini, A.(4);Armuzzi, A.(7);Gremese, E.(4);Guidi, L.(2);Pugliese, D.(2);
(1)Università degli studi di Milano, Dipartimento di scienze della salute, Milan, Italy;(2)Fondazione Policlinico A.Gemelli IRCCS, UOC CEMAD IBD Unit, Rome, Italy;(3)Fondazione Policlinico A.Gemelli IRCCS, UOSD di Immunologia Clinica, Rome, Italy;(4)Fondazione Policlinico A.Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy;(5)Fondazione Policlinico A.Gemelli IRCCS, UOC di Reumatologia, Rome, Italy;(6)Fondazione Policlinico A.Gemelli IRCCS, Immunology Research Core Facility, Rome, Italy;(7)Humanitas Clinical and Research Center IRCCS, Gastroenterologia, Milan, Italy;
